A systematic review of case studies testing a melatonergic agonist/ 5HT2c antagonist for individuals with obsessive compulsive disorder
• OCD is related to disruptions in the timing of sleep. • Agoemelatine is a melatonergic agonist/ 5 H T2c antagonist. • 10 case studies are reviewed. • Agomelatine reduced OCD symptoms in patients with sleep disruptions. • .gomelatine did not changes symptoms in patients without sleep disruptions....
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Coles, Meredith E. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Liquid chromatographic approach to investigation of dissolved organic matter adsorptive fractionation and competitive displacement on minerals - 2013, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:69 ; year:2020 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.janxdis.2019.102173 |
|---|
| Katalog-ID: |
ELV049037420 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV049037420 | ||
| 003 | DE-627 | ||
| 005 | 20230624151555.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200128s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.janxdis.2019.102173 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001064.pica |
| 035 | |a (DE-627)ELV049037420 | ||
| 035 | |a (ELSEVIER)S0887-6185(19)30499-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |q VZ |
| 082 | 0 | 4 | |a 540 |q VZ |
| 084 | |a 35.10 |2 bkl | ||
| 100 | 1 | |a Coles, Meredith E. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a A systematic review of case studies testing a melatonergic agonist/ 5HT2c antagonist for individuals with obsessive compulsive disorder |
| 264 | 1 | |c 2020 | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • OCD is related to disruptions in the timing of sleep. • Agoemelatine is a melatonergic agonist/ 5 H T2c antagonist. • 10 case studies are reviewed. • Agomelatine reduced OCD symptoms in patients with sleep disruptions. • .gomelatine did not changes symptoms in patients without sleep disruptions. | ||
| 650 | 7 | |a Circadian rhythms |2 Elsevier | |
| 650 | 7 | |a Treatment-resistant |2 Elsevier | |
| 650 | 7 | |a Obsessive compulsive disorder |2 Elsevier | |
| 650 | 7 | |a Sleep timing |2 Elsevier | |
| 650 | 7 | |a Agomelatine |2 Elsevier | |
| 650 | 7 | |a Review |2 Elsevier | |
| 700 | 1 | |a Goodman, Matthew H. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |t Liquid chromatographic approach to investigation of dissolved organic matter adsorptive fractionation and competitive displacement on minerals |d 2013 |g Amsterdam [u.a.] |w (DE-627)ELV016982789 |
| 773 | 1 | 8 | |g volume:69 |g year:2020 |g pages:0 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.janxdis.2019.102173 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 35.10 |j Physikalische Chemie: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 69 |j 2020 |h 0 | ||
| author_variant |
m e c me mec |
|---|---|
| matchkey_str |
colesmeredithegoodmanmatthewh:2020----:sseairveocssuisetnaeaoegcgns5tcnaoitoidvdas |
| hierarchy_sort_str |
2020 |
| bklnumber |
35.10 |
| publishDate |
2020 |
| allfields |
10.1016/j.janxdis.2019.102173 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001064.pica (DE-627)ELV049037420 (ELSEVIER)S0887-6185(19)30499-2 DE-627 ger DE-627 rakwb eng 540 VZ 540 VZ 35.10 bkl Coles, Meredith E. verfasserin aut A systematic review of case studies testing a melatonergic agonist/ 5HT2c antagonist for individuals with obsessive compulsive disorder 2020 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • OCD is related to disruptions in the timing of sleep. • Agoemelatine is a melatonergic agonist/ 5 H T2c antagonist. • 10 case studies are reviewed. • Agomelatine reduced OCD symptoms in patients with sleep disruptions. • .gomelatine did not changes symptoms in patients without sleep disruptions. Circadian rhythms Elsevier Treatment-resistant Elsevier Obsessive compulsive disorder Elsevier Sleep timing Elsevier Agomelatine Elsevier Review Elsevier Goodman, Matthew H. oth Enthalten in Elsevier Science Liquid chromatographic approach to investigation of dissolved organic matter adsorptive fractionation and competitive displacement on minerals 2013 Amsterdam [u.a.] (DE-627)ELV016982789 volume:69 year:2020 pages:0 https://doi.org/10.1016/j.janxdis.2019.102173 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.10 Physikalische Chemie: Allgemeines VZ AR 69 2020 0 |
| spelling |
10.1016/j.janxdis.2019.102173 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001064.pica (DE-627)ELV049037420 (ELSEVIER)S0887-6185(19)30499-2 DE-627 ger DE-627 rakwb eng 540 VZ 540 VZ 35.10 bkl Coles, Meredith E. verfasserin aut A systematic review of case studies testing a melatonergic agonist/ 5HT2c antagonist for individuals with obsessive compulsive disorder 2020 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • OCD is related to disruptions in the timing of sleep. • Agoemelatine is a melatonergic agonist/ 5 H T2c antagonist. • 10 case studies are reviewed. • Agomelatine reduced OCD symptoms in patients with sleep disruptions. • .gomelatine did not changes symptoms in patients without sleep disruptions. Circadian rhythms Elsevier Treatment-resistant Elsevier Obsessive compulsive disorder Elsevier Sleep timing Elsevier Agomelatine Elsevier Review Elsevier Goodman, Matthew H. oth Enthalten in Elsevier Science Liquid chromatographic approach to investigation of dissolved organic matter adsorptive fractionation and competitive displacement on minerals 2013 Amsterdam [u.a.] (DE-627)ELV016982789 volume:69 year:2020 pages:0 https://doi.org/10.1016/j.janxdis.2019.102173 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.10 Physikalische Chemie: Allgemeines VZ AR 69 2020 0 |
| allfields_unstemmed |
10.1016/j.janxdis.2019.102173 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001064.pica (DE-627)ELV049037420 (ELSEVIER)S0887-6185(19)30499-2 DE-627 ger DE-627 rakwb eng 540 VZ 540 VZ 35.10 bkl Coles, Meredith E. verfasserin aut A systematic review of case studies testing a melatonergic agonist/ 5HT2c antagonist for individuals with obsessive compulsive disorder 2020 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • OCD is related to disruptions in the timing of sleep. • Agoemelatine is a melatonergic agonist/ 5 H T2c antagonist. • 10 case studies are reviewed. • Agomelatine reduced OCD symptoms in patients with sleep disruptions. • .gomelatine did not changes symptoms in patients without sleep disruptions. Circadian rhythms Elsevier Treatment-resistant Elsevier Obsessive compulsive disorder Elsevier Sleep timing Elsevier Agomelatine Elsevier Review Elsevier Goodman, Matthew H. oth Enthalten in Elsevier Science Liquid chromatographic approach to investigation of dissolved organic matter adsorptive fractionation and competitive displacement on minerals 2013 Amsterdam [u.a.] (DE-627)ELV016982789 volume:69 year:2020 pages:0 https://doi.org/10.1016/j.janxdis.2019.102173 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.10 Physikalische Chemie: Allgemeines VZ AR 69 2020 0 |
| allfieldsGer |
10.1016/j.janxdis.2019.102173 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001064.pica (DE-627)ELV049037420 (ELSEVIER)S0887-6185(19)30499-2 DE-627 ger DE-627 rakwb eng 540 VZ 540 VZ 35.10 bkl Coles, Meredith E. verfasserin aut A systematic review of case studies testing a melatonergic agonist/ 5HT2c antagonist for individuals with obsessive compulsive disorder 2020 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • OCD is related to disruptions in the timing of sleep. • Agoemelatine is a melatonergic agonist/ 5 H T2c antagonist. • 10 case studies are reviewed. • Agomelatine reduced OCD symptoms in patients with sleep disruptions. • .gomelatine did not changes symptoms in patients without sleep disruptions. Circadian rhythms Elsevier Treatment-resistant Elsevier Obsessive compulsive disorder Elsevier Sleep timing Elsevier Agomelatine Elsevier Review Elsevier Goodman, Matthew H. oth Enthalten in Elsevier Science Liquid chromatographic approach to investigation of dissolved organic matter adsorptive fractionation and competitive displacement on minerals 2013 Amsterdam [u.a.] (DE-627)ELV016982789 volume:69 year:2020 pages:0 https://doi.org/10.1016/j.janxdis.2019.102173 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.10 Physikalische Chemie: Allgemeines VZ AR 69 2020 0 |
| allfieldsSound |
10.1016/j.janxdis.2019.102173 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001064.pica (DE-627)ELV049037420 (ELSEVIER)S0887-6185(19)30499-2 DE-627 ger DE-627 rakwb eng 540 VZ 540 VZ 35.10 bkl Coles, Meredith E. verfasserin aut A systematic review of case studies testing a melatonergic agonist/ 5HT2c antagonist for individuals with obsessive compulsive disorder 2020 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • OCD is related to disruptions in the timing of sleep. • Agoemelatine is a melatonergic agonist/ 5 H T2c antagonist. • 10 case studies are reviewed. • Agomelatine reduced OCD symptoms in patients with sleep disruptions. • .gomelatine did not changes symptoms in patients without sleep disruptions. Circadian rhythms Elsevier Treatment-resistant Elsevier Obsessive compulsive disorder Elsevier Sleep timing Elsevier Agomelatine Elsevier Review Elsevier Goodman, Matthew H. oth Enthalten in Elsevier Science Liquid chromatographic approach to investigation of dissolved organic matter adsorptive fractionation and competitive displacement on minerals 2013 Amsterdam [u.a.] (DE-627)ELV016982789 volume:69 year:2020 pages:0 https://doi.org/10.1016/j.janxdis.2019.102173 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.10 Physikalische Chemie: Allgemeines VZ AR 69 2020 0 |
| language |
English |
| source |
Enthalten in Liquid chromatographic approach to investigation of dissolved organic matter adsorptive fractionation and competitive displacement on minerals Amsterdam [u.a.] volume:69 year:2020 pages:0 |
| sourceStr |
Enthalten in Liquid chromatographic approach to investigation of dissolved organic matter adsorptive fractionation and competitive displacement on minerals Amsterdam [u.a.] volume:69 year:2020 pages:0 |
| format_phy_str_mv |
Article |
| bklname |
Physikalische Chemie: Allgemeines |
| institution |
findex.gbv.de |
| topic_facet |
Circadian rhythms Treatment-resistant Obsessive compulsive disorder Sleep timing Agomelatine Review |
| dewey-raw |
540 |
| isfreeaccess_bool |
false |
| container_title |
Liquid chromatographic approach to investigation of dissolved organic matter adsorptive fractionation and competitive displacement on minerals |
| authorswithroles_txt_mv |
Coles, Meredith E. @@aut@@ Goodman, Matthew H. @@oth@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
ELV016982789 |
| dewey-sort |
3540 |
| id |
ELV049037420 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV049037420</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624151555.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200128s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.janxdis.2019.102173</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001064.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV049037420</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0887-6185(19)30499-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.10</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Coles, Meredith E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">A systematic review of case studies testing a melatonergic agonist/ 5HT2c antagonist for individuals with obsessive compulsive disorder</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• OCD is related to disruptions in the timing of sleep. • Agoemelatine is a melatonergic agonist/ 5 H T2c antagonist. • 10 case studies are reviewed. • Agomelatine reduced OCD symptoms in patients with sleep disruptions. • .gomelatine did not changes symptoms in patients without sleep disruptions.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Circadian rhythms</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Treatment-resistant</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Obsessive compulsive disorder</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sleep timing</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Agomelatine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Review</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Goodman, Matthew H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Liquid chromatographic approach to investigation of dissolved organic matter adsorptive fractionation and competitive displacement on minerals</subfield><subfield code="d">2013</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV016982789</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:69</subfield><subfield code="g">year:2020</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.janxdis.2019.102173</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.10</subfield><subfield code="j">Physikalische Chemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">69</subfield><subfield code="j">2020</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| author |
Coles, Meredith E. |
| spellingShingle |
Coles, Meredith E. ddc 540 bkl 35.10 Elsevier Circadian rhythms Elsevier Treatment-resistant Elsevier Obsessive compulsive disorder Elsevier Sleep timing Elsevier Agomelatine Elsevier Review A systematic review of case studies testing a melatonergic agonist/ 5HT2c antagonist for individuals with obsessive compulsive disorder |
| authorStr |
Coles, Meredith E. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV016982789 |
| format |
electronic Article |
| dewey-ones |
540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
540 VZ 35.10 bkl A systematic review of case studies testing a melatonergic agonist/ 5HT2c antagonist for individuals with obsessive compulsive disorder Circadian rhythms Elsevier Treatment-resistant Elsevier Obsessive compulsive disorder Elsevier Sleep timing Elsevier Agomelatine Elsevier Review Elsevier |
| topic |
ddc 540 bkl 35.10 Elsevier Circadian rhythms Elsevier Treatment-resistant Elsevier Obsessive compulsive disorder Elsevier Sleep timing Elsevier Agomelatine Elsevier Review |
| topic_unstemmed |
ddc 540 bkl 35.10 Elsevier Circadian rhythms Elsevier Treatment-resistant Elsevier Obsessive compulsive disorder Elsevier Sleep timing Elsevier Agomelatine Elsevier Review |
| topic_browse |
ddc 540 bkl 35.10 Elsevier Circadian rhythms Elsevier Treatment-resistant Elsevier Obsessive compulsive disorder Elsevier Sleep timing Elsevier Agomelatine Elsevier Review |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m h g mh mhg |
| hierarchy_parent_title |
Liquid chromatographic approach to investigation of dissolved organic matter adsorptive fractionation and competitive displacement on minerals |
| hierarchy_parent_id |
ELV016982789 |
| dewey-tens |
540 - Chemistry |
| hierarchy_top_title |
Liquid chromatographic approach to investigation of dissolved organic matter adsorptive fractionation and competitive displacement on minerals |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV016982789 |
| title |
A systematic review of case studies testing a melatonergic agonist/ 5HT2c antagonist for individuals with obsessive compulsive disorder |
| ctrlnum |
(DE-627)ELV049037420 (ELSEVIER)S0887-6185(19)30499-2 |
| title_full |
A systematic review of case studies testing a melatonergic agonist/ 5HT2c antagonist for individuals with obsessive compulsive disorder |
| author_sort |
Coles, Meredith E. |
| journal |
Liquid chromatographic approach to investigation of dissolved organic matter adsorptive fractionation and competitive displacement on minerals |
| journalStr |
Liquid chromatographic approach to investigation of dissolved organic matter adsorptive fractionation and competitive displacement on minerals |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Coles, Meredith E. |
| container_volume |
69 |
| class |
540 VZ 35.10 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Coles, Meredith E. |
| doi_str_mv |
10.1016/j.janxdis.2019.102173 |
| dewey-full |
540 |
| title_sort |
a systematic review of case studies testing a melatonergic agonist/ 5ht2c antagonist for individuals with obsessive compulsive disorder |
| title_auth |
A systematic review of case studies testing a melatonergic agonist/ 5HT2c antagonist for individuals with obsessive compulsive disorder |
| abstract |
• OCD is related to disruptions in the timing of sleep. • Agoemelatine is a melatonergic agonist/ 5 H T2c antagonist. • 10 case studies are reviewed. • Agomelatine reduced OCD symptoms in patients with sleep disruptions. • .gomelatine did not changes symptoms in patients without sleep disruptions. |
| abstractGer |
• OCD is related to disruptions in the timing of sleep. • Agoemelatine is a melatonergic agonist/ 5 H T2c antagonist. • 10 case studies are reviewed. • Agomelatine reduced OCD symptoms in patients with sleep disruptions. • .gomelatine did not changes symptoms in patients without sleep disruptions. |
| abstract_unstemmed |
• OCD is related to disruptions in the timing of sleep. • Agoemelatine is a melatonergic agonist/ 5 H T2c antagonist. • 10 case studies are reviewed. • Agomelatine reduced OCD symptoms in patients with sleep disruptions. • .gomelatine did not changes symptoms in patients without sleep disruptions. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
A systematic review of case studies testing a melatonergic agonist/ 5HT2c antagonist for individuals with obsessive compulsive disorder |
| url |
https://doi.org/10.1016/j.janxdis.2019.102173 |
| remote_bool |
true |
| author2 |
Goodman, Matthew H. |
| author2Str |
Goodman, Matthew H. |
| ppnlink |
ELV016982789 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth |
| doi_str |
10.1016/j.janxdis.2019.102173 |
| up_date |
2024-07-06T20:27:39.079Z |
| _version_ |
1803862838168518656 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV049037420</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624151555.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200128s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.janxdis.2019.102173</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001064.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV049037420</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0887-6185(19)30499-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.10</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Coles, Meredith E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">A systematic review of case studies testing a melatonergic agonist/ 5HT2c antagonist for individuals with obsessive compulsive disorder</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• OCD is related to disruptions in the timing of sleep. • Agoemelatine is a melatonergic agonist/ 5 H T2c antagonist. • 10 case studies are reviewed. • Agomelatine reduced OCD symptoms in patients with sleep disruptions. • .gomelatine did not changes symptoms in patients without sleep disruptions.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Circadian rhythms</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Treatment-resistant</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Obsessive compulsive disorder</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sleep timing</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Agomelatine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Review</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Goodman, Matthew H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Liquid chromatographic approach to investigation of dissolved organic matter adsorptive fractionation and competitive displacement on minerals</subfield><subfield code="d">2013</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV016982789</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:69</subfield><subfield code="g">year:2020</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.janxdis.2019.102173</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.10</subfield><subfield code="j">Physikalische Chemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">69</subfield><subfield code="j">2020</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.4006395 |